^
    Back
    Association details:
    Biomarker:BIRC5 expression
    Cancer:Non Small Cell Lung Cancer
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

    Excerpt:
    ...Subjects with HCC, NSCLC, BlCa, or MSI-H subjects other than those with gastric or colorectal cancer must have evidence of survivin expression in their pre-treatment biopsy sample...
    Trial ID:
    KEYNOTE 903
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2020
    Title:

    Combination therapy with DPX-Survivac, intermittent low-dose cyclophosphamide (CPA) and pembrolizumab for the treatment of advanced and metastatic solid tumors: Early safety and efficacy results from a phase II basket study

    Published date:
    05/28/2020
    Excerpt:
    Subjects with survivin-expressing advanced, recurrent HCC, NSCLC, bladder and MSI-H tumors are enrolled to single arm…DPXSurvivac/CPA with pembrolizumab is well tolerated and shows early signs of clinical efficacy and disease control in advanced and metastatic solid tumors...
    Trial ID:
    KEYNOTE 903